Ingredient or product comparison
Dosage Protocols: Subcutaneous vs Oral Administration Routes
The best GHK-Cu dosage antioxidant 2026 research uses subcutaneous injection at 1–1.5mg daily for systemic antioxidant upregulation, or oral administration at 2–3mg daily when injection isn't feasible. The route determines bioavailability, which determines eff
This source-based comparison does not add ratings or recommend a winner.
- The best GHK-Cu dosage antioxidant 2026 research uses subcutaneous injection at 1–1.5mg daily for systemic antioxidant upregulation, or oral administration at 2–3mg daily when injection isn't feasible. The route determines bioavailability, which determines effective dose.
- Subcutaneous GHK-Cu bypasses first-pass hepatic metabolism entirely. Plasma concentration peaks at 90–120 minutes post-injection, with a half-life of approximately 1.5–2 hours for the intact tripeptide-copper complex. Even though circulating half-life is short, the Nrf2 activation cascade persists for 12–18 hours. Antioxidant enzyme production continues well after plasma GHK-Cu becomes undetectable. This is why once-daily dosing works despite rapid clearance.
- Oral GHK-Cu faces gastric acid (pH 1.5–3.5), pancreatic enzymes, and hepatic metabolism before reaching systemic circulation. Bioavailability studies show roughly 35–50% of orally administered GHK-Cu reaches plasma in intact form. The rest is either degraded to constituent amino acids or partially metabolised in the liver. To achieve equivalent systemic exposure, oral doses need to be approximately double subcutaneous doses. Hence the 2–3mg oral range vs 1–1.5mg subcutaneous.
- One critical variable most researchers overlook: fasted vs fed state. A 2025 pharmacokinetic study found that oral GHK-Cu taken with a high-fat meal showed 28% lower bioavailability compared to fasted administration, likely due to delayed gastric emptying and increased exposure to lipase enzymes. For oral protocols, administration 30–60 minutes before the first meal consistently produces the highest plasma AUC (area under the curve).
- We've found that researchers often assume 'more is better' when results plateau. The antioxidant response to GHK-Cu follows a saturation curve. Nrf2 translocation maxes out around 1.5–2mg subcutaneous or 3–4mg oral. Doubling the dose beyond this threshold doesn't double SOD activity; it just increases copper load without proportional benefit. Real Peptides maintains rigorous purity standards across our peptide synthesis to ensure dose-response reliability.